Kathryn Stephenson

Kathryn E. Stephenson, M.D., M.P.H.

Kathryn E. Stephenson, M.D., M.P.H.

Principal Investigator and CTU Principal Investigator
Clinical Trials Unit

Assistant Professor of Medicine, Harvard Medical School
Director, Clinical Trials Unit, Center for Virology and Vaccine Research, BIDMC
Staff Physician, Division of Infectious Diseases, BIDMC
Associate Member, Ragon Institute of MGH, MIT and Harvard

T: 617-735-4556
F: 617-735-4566

Dr. Stephenson is a physician-scientist who specializes in infectious diseases and HIV immunology, and the goal of her research is to develop novel biomedical interventions to prevent and treat HIV and emerging infectious diseases such as Zika virus. In particular, she is interested in the design and evaluation of HIV vaccines and monoclonal antibodies that can be effective in the face of tremendous HIV sequence diversity, as well as in the development of Zika vaccines. As an immunologist, her expertise is in the extensive epitope mapping of cellular and humoral immune responses. As a clinical investigator, her expertise is in the translation of novel vaccines and monoclonal antibodies into First-in-Human, Phase 1 clinical trials, and she is the Director of the Center for Virology and Vaccine Research Clinical Trials Unit. She is also Associate Editor of Clinical Immunology.


  • Williams College, Williamstown, MA, B.A., 1996 (Anthropology)
  • Joseph L. Mailman School of Public Health, Columbia University, New York, NY, M.P.H., 2001
  • New York University School of Medicine, New York, NY, M.D., 2005


  • Residency, Columbia University Medical Center, 2005-2008 (Internal Medicine)
  • Clinical Fellowship, Massachusetts General Hospital, Brigham and Women’s Hospital, 2008-2009 (Infectious Diseases)
  • Postdoctoral Fellowship, Center for Virology and Vaccine Research, Beth Israel Deaconess Medial Center, 2009-2011 (Immunology)


  • 1997-1999, Research Assistant/Associate, HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA
  • 2000, Intern, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland
  • 2007, Jay I. Meltzer Fellow in Medical Ethics, Columbia University, New York
  • 2011-2016, Associate Physician, Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA
  • 2011-2015, Instructor in Medicine, Harvard Medical School, Boston, MA
  • 2011-2016, Consulting Staff, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • 2014-present, Staff Physician, Division of Infectious Diseases, BIDMC, Boston, MA
  • 2015-present, Assistant Professor of Medicine, Harvard Medical School, 2015-present
  • 2017-present, Associate Member, Ragon Institute of MGH, MIT and Harvard


  • 1994 Gargoyle Society Alumni Scholarship, Williams College
  • 1995 Ruchman Fellow, Oakley Center for Humanities and Social Sciences, Williams College
  • 1996 Benjamin B. Wainwright 1920 Prize in English, Williams College
  • 2005 Jack and Diana Nelson Award for Scholarship and Professionalism, NYU School of Medicine
  • 2008 13th Annual Joseph N. Muschel Award, Columbia University, New York-Presbyterian Hospital
  • 2011 AIDS Vaccine 2011 Conference Scholarship, Global HIV Vaccine Enterprise
  • 2012 AIDS Vaccine 2012 Conference Scholarship, Global HIV Vaccine Enterprise
  • 2013 Maxwell Finland Award for Research Excellence, Massachusetts Infectious Diseases Society
  • 2014 Center for AIDS Research Scholar Award, Harvard University
  • 2016 103.3 AMP Radio Badass Chick of the Week
  • 2016 The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy, Global HIV Vaccine Enterprise


  • Sadoff, Jerald, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M. De Groot, Jeroen Stoop, Sarah Tete, Wim VanDamme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan De Hoon, William Smith, Kathryn Stephenson, Stephen De Rosa, Kristen Cohen, Juliana McElrath, Emmanuel Cormier, Gert Scheper, Dan Barouch, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Johan Van Hoof, and Henneke Schuitemaker. "Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine." The New England Journal of Medicine (2021). Print. [Article]

  • Stephenson KE, Wagh K, Korber B, Barouch DH. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Annu Rev Immunol. 2020;38:673‐703. doi:10.1146/annurev-immunol-080219-023629 [Article]

  • Dussupt V, Sankhala RS, Gromowski GD, et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat Med. 2020;26(2):228‐235. doi:10.1038/s41591-019-0746-2 [Article]

  • Stephenson KE, Wegmann F, Tomaka F, et al. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22) [published online ahead of print, 2020 Feb 17] [published correction appears in Lancet HIV. 2020 Feb 28;:]. Lancet HIV. 2020;S2352-3018(20)30001-1. doi:10.1016/S2352-3018(20)30001-1 [Article]

  • Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72. [Article]

  • Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6. PubMed PMID: 30047376; PubMed Central PMCID: PMC6192527. [Article]

  • Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One 2018; 13:e0205139. [Article]

  • Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector. J. Infect. Dis. 2018; 218:633-644. [Article]

  • Bricault CA, Kovacs JM, Badamchi-Zadeh A, McKee K, Shields JL, Gunn BM, Neubauer GH, Ghantous F, Jennings J, Gillis L, Perry J, Nkolola JP, Alter G, Chen B, Stephenson KE, Doria-Rose N, Mascola JR, Seaman MS, Barouch DH. Neutralizing antibody responses following long-term vaccination with HIV-1 Env gp140 in guinea pigs. J. Virol. 2018; 92:e00369-18. [Article]

  • Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5. PubMed PMID: 29217375; PubMed Central PMCID: PMC5884730. [Article]